Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly monitored during the ...

Oncotarget recently published "A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe ...

Dr. Mikhail V. Blagosklonny, M.D., Ph.D., Editor-in-Chief of Oncotarget, and Professor, at Roswell Park Cancer Institute, published "The goal of geroscience is life extension" which was selected as ...

A new case report was published in Volume 17 of Oncotarget on May 4, 2026, titled “Laryngeal leiomyosarcoma: A rare case ...

Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options. Publication ...

A new editorial paper titled "Therapeutic potentials and challenges of cytostatic persister cancer cells" has been published in Oncotarget. Cancer cells that remain viable despite treatment constitute ...

Oncotarget published "Nanoparticle T cell engagers for the treatment of acute myeloid leukemia" which reported that Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year ...

The landscape of treatment and overall survival analysis of elderly patients with advanced breast cancer in China National Cancer Center. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A ...

OncoTarget® 500 is powered by PGDx Elio Tissue Complete and assesses cancer pathology by analyzing over 500 genes to detect genetic alterations associated with cancer growth. OncoTarget®500 genomic ...